# Spinal Muscular Atrophy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/spinal-muscular-atrophy

> 4 upcoming FDA catalysts in spinal Muscular Atrophy: SPINRAZA (nusinersen, BIIB) on Sep to Dec 2027 (topline data readout); SPINRAZA (nusinersen, BIIB) on September 2027 (primary completion); salanersen (BIIB) on Jun to Sep 2028 (topline data readout); salanersen (BIIB) on June 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 22, 2025 | [ISEMBYLD (apitegromab) PDUFA date](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy | completed, complete response letter | "Exhibit 99.1 target action date for apitegromab of September 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm)) |
| Sep to Dec 2027 | [SPINRAZA (nusinersen) topline data readout](https://sec-api.dev/pdufa/nusinersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT05067790 (A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05067790)) |
| September 2027 | [SPINRAZA (nusinersen) primary completion](https://sec-api.dev/pdufa/nusinersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT05067790 (A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05067790)) |
| Jun to Sep 2028 | [Salanersen topline data readout](https://sec-api.dev/pdufa/salanersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT07444476 (A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-23 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444476)) |
| June 2028 | [Salanersen primary completion](https://sec-api.dev/pdufa/salanersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT07444476 (A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-23 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444476)) |

## Drugs

- [ISEMBYLD (apitegromab)](https://sec-api.dev/pdufa/apitegromab) (SRRK)
- [SPINRAZA (nusinersen)](https://sec-api.dev/pdufa/nusinersen) (BIIB)
- [Salanersen](https://sec-api.dev/pdufa/salanersen) (BIIB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/spinal-muscular-atrophy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Spinal Muscular Atrophy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/spinal-muscular-atrophy

```bibtex
@misc{secapidev_indications_spinal_muscular_atrophy_20261116,
  title        = {Spinal Muscular Atrophy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/spinal-muscular-atrophy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_spinal_muscular_atrophy_20261116","title":"Spinal Muscular Atrophy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/spinal-muscular-atrophy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
